LAIDLAW & COMPANY (UK) LTD.
546 Fifth Avenue, 5th Floor
New York, New York 10036
May 12, 2017
VIA EDGAR
Division of Corporation Finance
Securities and Exchange Commission
Washington, D.C. 20549
| | Re: | Mabvax Therapeutics Holdings, Inc. Registration Statement on Form S-1 File No. 333-216016 |
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), we, the representative of the several underwriters (the “Representative”), hereby join in the request of the Company that the effective time of the above-referenced Registration Statement be accelerated so that it will be declared effective at 4:30 p.m. Eastern Time on May 12, 2017, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act, please be advised that through the date hereof, the preliminary prospectus, dated March 29, 2017 and the preliminary prospectus, dated May 12, 2017, was distributed (either in print or electronic form) approximately as follows:
| Sent to Underwriters: 0 |
| Sent to Dealers: 1 |
| Sent to Institutional Investors: 50 |
| Sent to Others: 100 |
| Total: 151 |
The Representative confirms on behalf of itself and the several underwriters that they have complied and will continue to comply with the requirements of Rule 15c2-8 promulgated under of the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.
Very truly yours,
LAIDLAW & COMPANY (UK) LTD.
as representative of the underwriters
By: /s/ Alex Shtaynberger
Name: Alex Shtaynberger
Title: National Branch Manager
